Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting

An announcement from Arcutis Biotherapeutics ( (ARQT) ) is now available.

On June 12, 2025, Arcutis Biotherapeutics held its 2025 Annual Meeting of Stockholders, where all proposed matters were approved by the shareholders. The meeting included the election of three Class II directors, ratification of Ernst & Young LLP as the independent auditor, and approval of executive compensation. Additionally, the company revised its Non-Employee Director Compensation Plan to enhance its corporate governance practices and attract qualified board members.

The most recent analyst rating on (ARQT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Arcutis Biotherapeutics stock, see the ARQT Stock Forecast page.

Spark’s Take on ARQT Stock

According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.

Arcutis Biotherapeutics scores moderately due to robust revenue growth and promising pipeline developments. However, persistent unprofitability, negative cash flows, and valuation challenges weigh on the score. The mixed technical indicators and positive corporate event contribute modestly to the overall assessment.

To see Spark’s full report on ARQT stock, click here.

More about Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing innovative dermatological treatments. The company is known for its commitment to addressing unmet needs in dermatology through its research and development efforts.

Average Trading Volume: 2,225,178

Technical Sentiment Signal: Buy

Current Market Cap: $1.6B

Learn more about ARQT stock on TipRanks’ Stock Analysis page.